Helix BioPharma Corp. Announces Fiscal Third Quarter 2020 Results

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2020.

Management’s discussion and analysis of financial condition and results of operations